Subscribe
shutterstock_1425438833_ii-studio
II.studio / Shutterstock.com
9 September 2019Big PharmaSarah Morgan

Novartis and BenevolentAI sign AI oncology deal

Swiss pharmaceutical company Novartis has united with BenevolentAI to aid in the discovery and development of new treatments.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Bayer begins $240m AI drug discovery project with Exscientia
10 January 2020   Germany-based Bayer is collaborating with Exscientia, an artificial intelligence (AI)-driven drug discovery company, to accelerate the discovery of small molecule drugs focused on cardiovascular disease and oncology.
Asia
Insilico Medicine signs $200m AI drug discovery deal
10 October 2019   Hong Kong-based Insilico Medicine has agreed an artificial intelligence breast cancer drug discovery partnership worth a potential $200 million with a Chinese pharmaceutical company.
Big Pharma
AstraZeneca partners on AI drug discovery collaboration
2 May 2019   AstraZeneca has begun collaborating with UK-headquartered artificial intelligence company BenevolentAI to use AI and machine learning for the discovery and development of new treatments.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Big Pharma
Bayer begins $240m AI drug discovery project with Exscientia
10 January 2020   Germany-based Bayer is collaborating with Exscientia, an artificial intelligence (AI)-driven drug discovery company, to accelerate the discovery of small molecule drugs focused on cardiovascular disease and oncology.
Asia
Insilico Medicine signs $200m AI drug discovery deal
10 October 2019   Hong Kong-based Insilico Medicine has agreed an artificial intelligence breast cancer drug discovery partnership worth a potential $200 million with a Chinese pharmaceutical company.
Big Pharma
AstraZeneca partners on AI drug discovery collaboration
2 May 2019   AstraZeneca has begun collaborating with UK-headquartered artificial intelligence company BenevolentAI to use AI and machine learning for the discovery and development of new treatments.

More on this story

Big Pharma
Bayer begins $240m AI drug discovery project with Exscientia
10 January 2020   Germany-based Bayer is collaborating with Exscientia, an artificial intelligence (AI)-driven drug discovery company, to accelerate the discovery of small molecule drugs focused on cardiovascular disease and oncology.
Asia
Insilico Medicine signs $200m AI drug discovery deal
10 October 2019   Hong Kong-based Insilico Medicine has agreed an artificial intelligence breast cancer drug discovery partnership worth a potential $200 million with a Chinese pharmaceutical company.
Big Pharma
AstraZeneca partners on AI drug discovery collaboration
2 May 2019   AstraZeneca has begun collaborating with UK-headquartered artificial intelligence company BenevolentAI to use AI and machine learning for the discovery and development of new treatments.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB